Impact of polymorphisms within genes involved in regulating DNA methylation in patients with metastatic colorectal cancer enrolled in three independent, randomised, open-label clinical trials: a meta-analysis from TRIBE, MAVERICC and FIRE-3.
Clinical trials
Colorectal cancer
DNA methylation
Meta-analysis
Single-nucleotide polymorphism
Journal
European journal of cancer (Oxford, England : 1990)
ISSN: 1879-0852
Titre abrégé: Eur J Cancer
Pays: England
ID NLM: 9005373
Informations de publication
Date de publication:
04 2019
04 2019
Historique:
received:
19
12
2018
revised:
19
01
2019
accepted:
25
01
2019
pubmed:
11
3
2019
medline:
27
5
2020
entrez:
11
3
2019
Statut:
ppublish
Résumé
CpG island DNA hypermethylation and global DNA hypomethylation are hallmark characteristics of colorectal cancer (CRC). Therefore, we aim to explore the effect of genetic variations within the genes that regulate the DNA methylation and demethylation pathways on outcomes in patients with metastatic CRC (mCRC) treated with first-line therapy and enrolled in three independent, randomised, open-label clinical trials. A total of 884 patients with mCRC enrolled in TRIBE, MAVERICC and FIRE-3 trials were included. Single-nucleotide polymorphisms (SNPs) within genes involved in DNA methylation and demethylation pathways were analysed. The prognostic value of each SNP across all treatment arms was quantified using the inverse-variance-weighted effect size, a meta-analysis approach implemented in the METASOFT software. In the meta-analysis, DNMT3A rs11681717 was significantly associated with overall survival (hazard ratio = 1.26; 95% confidence interval [CI] 1.08-1.46; P = 0.002; false discovery rate [FDR] = 0.016), accounting for seven tests in the DNA methylation pathway. In addition, there was suggestive evidence of association for ten-eleven translocation (TET) genes variance with tumour response (TET1 rs3814177, odds ratio [OR] = 0.76, 95% CI 0.59-0.97, P = 0.025, FDR = 0.087; TET3 rs7560668, OR = 1.44; 95% CI 1.10-1.89; P = 0.009; FDR = 0.062). We showed that polymorphisms within the genes responsible for the DNA methylation and demethylation machineries are correlated with outcomes in patients with mCRC who were enrolled in three independent, randomised, open-label, phase II/III clinical trials. In addition, we demonstrated the feasibility of a meta-analysis approach to identify stronger and more convincing association between gene polymorphisms and outcome, potentially leading the way to a new method of analysis for similar data set.
Sections du résumé
BACKGROUND
CpG island DNA hypermethylation and global DNA hypomethylation are hallmark characteristics of colorectal cancer (CRC). Therefore, we aim to explore the effect of genetic variations within the genes that regulate the DNA methylation and demethylation pathways on outcomes in patients with metastatic CRC (mCRC) treated with first-line therapy and enrolled in three independent, randomised, open-label clinical trials.
METHODS
A total of 884 patients with mCRC enrolled in TRIBE, MAVERICC and FIRE-3 trials were included. Single-nucleotide polymorphisms (SNPs) within genes involved in DNA methylation and demethylation pathways were analysed. The prognostic value of each SNP across all treatment arms was quantified using the inverse-variance-weighted effect size, a meta-analysis approach implemented in the METASOFT software.
RESULTS
In the meta-analysis, DNMT3A rs11681717 was significantly associated with overall survival (hazard ratio = 1.26; 95% confidence interval [CI] 1.08-1.46; P = 0.002; false discovery rate [FDR] = 0.016), accounting for seven tests in the DNA methylation pathway. In addition, there was suggestive evidence of association for ten-eleven translocation (TET) genes variance with tumour response (TET1 rs3814177, odds ratio [OR] = 0.76, 95% CI 0.59-0.97, P = 0.025, FDR = 0.087; TET3 rs7560668, OR = 1.44; 95% CI 1.10-1.89; P = 0.009; FDR = 0.062).
CONCLUSIONS
We showed that polymorphisms within the genes responsible for the DNA methylation and demethylation machineries are correlated with outcomes in patients with mCRC who were enrolled in three independent, randomised, open-label, phase II/III clinical trials. In addition, we demonstrated the feasibility of a meta-analysis approach to identify stronger and more convincing association between gene polymorphisms and outcome, potentially leading the way to a new method of analysis for similar data set.
Identifiants
pubmed: 30852420
pii: S0959-8049(19)30146-7
doi: 10.1016/j.ejca.2019.01.105
pmc: PMC6436973
mid: NIHMS1521586
pii:
doi:
Substances chimiques
DNMT3A protein, human
0
DNA (Cytosine-5-)-Methyltransferases
EC 2.1.1.37
DNA Methyltransferase 3A
EC 2.1.1.37
Types de publication
Journal Article
Meta-Analysis
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
138-147Subventions
Organisme : NCI NIH HHS
ID : P30 CA014089
Pays : United States
Informations de copyright
Copyright © 2019 Elsevier Ltd. All rights reserved.
Références
Mol Carcinog. 2007 Sep;46(9):766-72
pubmed: 17538945
Proc Natl Acad Sci U S A. 2007 Oct 2;104(40):15805-10
pubmed: 17890317
Science. 2009 May 15;324(5929):930-5
pubmed: 19372391
Cell Cycle. 2009 Jun 1;8(11):1698-710
pubmed: 19411852
Gastroenterology. 2009 Sep;137(3):902-13, 913.e1-11
pubmed: 19454286
Clin Cancer Res. 2009 Jun 1;15(11):3663-71
pubmed: 19470733
Br J Cancer. 2009 Aug 18;101(4):699-706
pubmed: 19638978
Carcinogenesis. 2010 Jan;31(1):27-36
pubmed: 19752007
Int J Cancer. 2011 Feb 1;128(3):551-61
pubmed: 20473858
N Engl J Med. 2010 Dec 16;363(25):2424-33
pubmed: 21067377
Am J Hum Genet. 2011 May 13;88(5):586-98
pubmed: 21565292
Nat Rev Gastroenterol Hepatol. 2011 Oct 18;8(12):686-700
pubmed: 22009203
Cancer Sci. 2012 Apr;103(4):670-6
pubmed: 22320381
PLoS Comput Biol. 2012;8(12):e1002822
pubmed: 23300413
Nat Rev Genet. 2013 Jun;14(6):379-89
pubmed: 23657481
Nat Rev Mol Cell Biol. 2013 Jun;14(6):341-56
pubmed: 23698584
J Hum Genet. 2013 Jul;58(7):421-7
pubmed: 23719188
Nature. 2013 Aug 8;500(7461):222-6
pubmed: 23812591
Oncotarget. 2014 Feb 15;5(3):587-98
pubmed: 24583822
World J Gastroenterol. 2014 Jul 7;20(25):8201-8
pubmed: 25009393
Lancet Oncol. 2014 Sep;15(10):1065-75
pubmed: 25088940
N Engl J Med. 2014 Oct 23;371(17):1609-18
pubmed: 25337750
Oncogene. 2015 Aug 6;34(32):4168-76
pubmed: 25362856
Cancer Epidemiol Biomarkers Prev. 2015 Mar;24(3):512-519
pubmed: 25587051
Annu Rev Nutr. 2015;35:545-64
pubmed: 25974700
Nat Genet. 2015 Aug;47(8):856-60
pubmed: 26121088
Nat Commun. 2015 Jul 07;6:7138
pubmed: 26151821
J Invest Surg. 2015;28(6):346-53
pubmed: 26203494
Am J Physiol Cell Physiol. 2015 Oct 15;309(8):C511-21
pubmed: 26289750
Nature. 2015 Oct 1;526(7571):68-74
pubmed: 26432245
Science. 2015 Dec 11;350(6266):1391-6
pubmed: 26541605
Sci Rep. 2015 Dec 03;5:17568
pubmed: 26631571
Clin Epigenetics. 2016 Mar 02;8:25
pubmed: 26941852
Cell. 2016 Feb 25;164(5):1073
pubmed: 27064190
Genetics. 2016 Oct;204(2):783-798
pubmed: 27489002
Proc Natl Acad Sci U S A. 2016 Sep 13;113(37):10238-44
pubmed: 27573823
Cancer Epidemiol Biomarkers Prev. 2017 Jan;26(1):126-135
pubmed: 27697780
Clin Cancer Res. 2017 Aug 1;23(15):4242-4250
pubmed: 28351930
Nat Genet. 2017 Oct;49(10):1511-1516
pubmed: 28892059
Biochim Biophys Acta Rev Cancer. 2017 Dec;1868(2):439-448
pubmed: 28939182
Oncogene. 2018 Feb 1;37(5):566-577
pubmed: 28991233
Nat Rev Cancer. 2017 Nov;17(11):692-704
pubmed: 29026206
Semin Cancer Biol. 2018 Aug;51:59-67
pubmed: 29102482
Biomed Pharmacother. 2018 Feb;98:433-439
pubmed: 29278853
Clin Epigenetics. 2018 Mar 14;10:35
pubmed: 29564023
Clin Cancer Res. 2018 Sep 17;:null
pubmed: 30224341
Stat Methods Med Res. 1993;2(2):121-45
pubmed: 8261254